Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report

Am J Hematol. 2005 Sep;80(1):50-4. doi: 10.1002/ajh.20424.

Abstract

We report for the first time a child with chronic granulomatous disease (CGD) who developed acute lymphoblastic leukemia (ALL). The diagnosis of CGD was made at the age of 4 months, by studies of his neutrophil functions. The superoxide production of the cells was negligible, as was the bactericidal activity. He was found to have a deficiency of the gp91(phox) subunit of the leukocyte NADPH oxidase, with the X-linked inheritance of the disease. DNA analysis revealed a C nucleotide insertion between C1028 and T1029. This insertion has not been described before and causes a frameshift and a premature stop codon at amino-acid position 347. The mother was found to be a carrier of this mutation. At the age of 16 months, the patient developed T-cell ALL. He was treated for 2 years, and today, 10 years since the diagnosis, he is disease-free. During the course of ALL and later, he suffered from recurrent severe pyogenic infections, but careful detection of the etiological agent and promptly instituted specific treatment resulted in his complete recovery. Although primary immune deficiencies have been reported to have an increased tendency to develop malignancies, until now there have been no reports of CGD patients with ALL.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Base Sequence
  • Female
  • Granulomatous Disease, Chronic / complications
  • Granulomatous Disease, Chronic / drug therapy
  • Granulomatous Disease, Chronic / genetics*
  • Humans
  • Infant
  • Male
  • Membrane Glycoproteins / genetics*
  • Molecular Sequence Data
  • Mutation*
  • NADPH Oxidase 2
  • NADPH Oxidases / genetics*
  • Nuclear Family
  • Pedigree
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Membrane Glycoproteins
  • CYBB protein, human
  • NADPH Oxidase 2
  • NADPH Oxidases